Company Analysis

Pliant Therapeutics, Inc. (PLRX)

Nasdaq: PLRX · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2018
Grade4.7
◀ Past 4.4● Present 5.4▶ Future 4.3
4 est.

Who runs Pliant Therapeutics, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Coulie Bernard
President and CEO. First filing Apr 2020, latest Apr 17, 2026, 22 filings in all.
Officers reporting now
5
of 13 people with a filing in the last fifteen months
Directors reporting now
8
23 people on the record since 2020
Officerssales are open-market, Oct 2, 2025 to Oct 2, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Raben DavidChief Medical OfficerOct 2026Oct 2, 2026none
Coulie BernardPresident and CEOApr 2020Apr 17, 20261 · $100,000
Cummings Keith LamontChief Financial OfficerApr 2020Apr 17, 20261 · $0.00
Kuo MinnieChief Operating OfficerDec 2025Apr 17, 20261 · $0.00
Cheung LilyChief Human Resource OfficerJan 2023Apr 17, 20261 · $0.00
Directorssales are open-market, Oct 2, 2025 to Oct 2, 2026
NameRoleFirst filingLatest filingSales, 12 months
Borellini FlaviadirectorJul 2026Jul 13, 2026none
Iannone RobertdirectorJul 2026Jul 13, 2026none
Cline Darren SdirectorMar 2023Jun 12, 2026none
Crowell Gayle AdirectorJun 2020Jun 12, 2026none
Curnutte John TdirectorJun 2020Jun 12, 2026none
Huh HoyoungdirectorJun 2020Jun 12, 2026none
Krognes Steve E.directorJun 2024Jun 12, 2026none
Mccourt Thomas AdirectorMar 2023Jun 12, 2026none
Earlier names on the record21, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton PLRX · research, not advice